Trial Profile
A Phase III Trial to Evaluate the Efficacy and Safety of the Combination Therapy of Capecitabine and Oxaliplatin (XELOX) in Comparison to the Combination Therapy of Fluorouracil/Folinic Acid and Oxaliplatin (FOLFOX) in Patients With AGC
Status:
Discontinued
Phase of Trial:
Phase III
Latest Information Update: 07 Nov 2021
Price :
$35
*
At a glance
- Drugs Capecitabine (Primary) ; Fluorouracil; Folinic acid; Oxaliplatin
- Indications Gastric cancer
- Focus Therapeutic Use
- 02 Nov 2014 Status changed from recruiting to discontinued as reported by ClinicalTrials.gov record.
- 14 Jan 2013 New trial record